Evidence map›Paper›PMID 32723834›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020

Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors.

Sailing Shi, Shengqing Gu, Tong Han, Wubing Zhang, Lei Huang, Ziyi Li, Deng Pan, Jingxin Fu, Jun Ge, Myles Brown and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Immunometabolism (Cobham, Surrey) · 2023
    Review
  17. Review
  18. Translational cancer research · 2022
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Sailing Shi *Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Shengqing Gu *Department of Data Science, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Tong HanClinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Wubing ZhangClinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Lei HuangClinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Ziyi LiClinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Deng PanDepartment of Basic Medical Sciences, Tsinghua University, Beijing, China.
Jingxin FuClinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.ORCID 0000-0002-4028-3661
Jun GeClinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Myles BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Peng ZhangClinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Peng JiangCancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. xsliu@ds.dfci.harvard.edu peng.jiang@nih.gov kai_wucherpfennig@dfci.harvard.edu.ORCID 0000-0002-7828-5486
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts. xsliu@ds.dfci.harvard.edu peng.jiang@nih.gov kai_wucherpfennig@dfci.harvard.edu.
X Shirley LiuDepartment of Data Science, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. xsliu@ds.dfci.harvard.edu peng.jiang@nih.gov kai_wucherpfennig@dfci.harvard.edu.
Dana-Farber Cancer Institute · USShanghai Pulmonary Hospital · CNNational Institutes of Health · USTsinghua University · CN

Funding

Regulators of Cancer Immunotherapy ResponseR01CA234018 · NCI · DANA-FARBER CANCER INST · PI BROWN, MYLES A · 2019 to 2022
$2.3M
NCI NIH HHS R01 CA234018
6 · The paper itself

Abstract

purposeImmune checkpoint blockade has shown remarkable efficacy, but in only a minority of patients with cancer, suggesting the need to develop additional treatment strategies. Aberrant glycosylation in tumors, resulting from the dysregulated expression of key enzymes in glycan biosynthesis, modulates the immune response. However, the role of glycan biosynthesis enzymes in antitumor immunity is poorly understood. We aimed to study the immunomodulatory effects of these enzymes. EXPERIMENTAL

designWe integrated transcriptional profiles of treatment-naïve human tumors and functional CRISPR screens to identify glycometabolism genes with immunomodulatory effects. We further validated our findings using

resultsWe identified

conclusions

Indexed as

alpha-MannosidaseB7-H1 AntigenCell Line, TumorCoculture TechniquesHumansImmune Checkpoint InhibitorsImmunomodulationLymphocytes, Tumor-InfiltratingNeoplasmsPolysaccharidesT-LymphocytesXenograft Model Antitumor Assaysalpha-MannosidaseB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPolysaccharides

Identifiers

PMID32723834
PMCPMC8500537
OpenAlexW3046182443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.